With this acquisition, Abcam will enhance its manufacturing and product development capability, particularly in the exciting area of assay development.
Following the acquisition, the employees of MitoSciences will join Abcam’s team.
Abcam CEO Jonathan Milner said they are delighted to strengthen their business in this exciting research area and look forward to welcoming the employees of MitoSciences into the Abcam team.
"This kind of acquisition adds value for our business and customers, and we will continue to appraise new acquisition opportunities as they arise," Milner said.